Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 4/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PTAFR | P25105 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671798 | 0.82 | KHK (0.51) | KHKMGAMGAASIMGAM2 | |
| SCHEMBL3666625 | 0.80 | SLC6A4 (0.47) | KHKHRH3KCNH2 | |
| SCHEMBL3737493 | 0.80 | SLC6A4 (0.47) | KHKHRH3KCNH2 | |
| SCHEMBL4937472 | 0.76 | HRH3 (0.58) | HRH3PTAFRKCNH2 | |
| SCHEMBL4945186 | 0.75 | HRH3 (0.59) | HRH3KCNH2 | |
| SCHEMBL3733490 | 0.75 | HRH3 (0.59) | HRH3KCNH2 | |
| SCHEMBL3722716 | 0.74 | HRH3 (0.66) | HRH3KCNH2 | |
| SCHEMBL3725620 | 0.74 | PTAFR (0.44) | KHKHRH3PTAFRKCNH2 | |
| SCHEMBL4944613 | 0.73 | HRH3 (0.68) | HRH3KCNH2 | |
| SCHEMBL4945837 | 0.73 | HRH3 (0.68) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | KHK 4389/4885MGAM 4390/4885GAA 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.